ROTEM and vitro reversal of warfarin with APCC
Article Sidebar
Main Article Content
Abstract
Background: Warfarin-treated patients with a prolonged Prothrombin Time (PT) can have a normal rotational thromboelastometry (ROTEM) clotting time (CT). A previous in vitro study found that activated prothrombin complex concentrates (APCC) could reverse an albumin-induced coagulopathy monitored with ROTEM, but that prothrombin complex concentrates (PCC) could not. The aim of this study was to investigate the ability of ROTEM to monitor the in vitro reversal of warfarin-induced coagulopathy using APCC and to define an APCC dose response.
Method: During the routine control of PT in 27 patients treated with warfarin, one extra 4.5 ml test tube of citrated whole blood was retrieved. Two concentrations of tissue factor ROTEM tissue factor (TF) activating reagents were used: a standard ROTEM ExTEM and a diluted 1:19000 concentration. The effects of two separate doses of APCC added in vitro corresponding to in vivo doses of 50 IE or 100 IE/kg were then studied on the ROTEM.
Results: The ROTEM EXTEM CT was prolonged beyond the upper normal range of 68 s in patients with PT >3.0, with a correlation coefficient of 0.88 to PT. ROTEM with the ExTEM reagent alongside high and low doses of APCC resulted in a significant shortening of median CT, both compared to baseline (100 s) and after low (65 s) and high doses (57 s). This was most evident in patients with PT >2.0. ROTEM signals of clot propagation to clot formation time (CFT) and α angle had the reverse pattern. There was no effect on maximal clot strength with APCC. With the diluted TF no CT shortening was found with APCC.
Conclusion: A clear dose response of APCC added in vitro to correct the effects of warfarin on ROTEM EXTEM CT was verified. ROTEM CT should be tested with non-activated PCC for in vivo reversal of warfarin in patients along with verification of a normalised PT. Further studies are needed to verify if a ROTEM CT in the lower normal range of <57-65 s, as found in our in vitro APCC-spiked warfarin blood, is safe for invasive procedures.
Downloads
Article Details
Copyright (c) 2019 Kornhall L, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, et al. (2008) American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 160-198. Link: https://goo.gl/BQ9zZ9
Horsti J (2002) Comparison of quick and owren prothrombin time with regard to the harmonisation of the International Normalised Ratio (INR) system. Clin Chem Lab Med 40: 399-403. Link: https://goo.gl/Ur6rsm
Vine AK (2009) Recent advances in haemostasis and thrombosis. Retina 29: 1-7. Link: https://goo.gl/gECKVs
Ganter MT, Hofer CK (2008) Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 106: 1366-1375. Link: https://goo.gl/kXxE3A
Whiting D, DiNardo JA (2014) TEG and ROTEM: technology and clinical applications. Am J Hematol 89: 228-232. Link: https://goo.gl/4XTG7o
Larsson A, Tynngård N, Kander T, Bonnevier J, Schött U (2015) Comparison of point-of-care hemostatic assays, routine coagulation tests, and outcome scores in critically ill patients. J Crit Care 30: 1032-1038. Link: https://goo.gl/9L3PPC
Schmidt DE, Holmström M, Majeed A, Näslin D, Wallén H, Ågren, et al. (2015) Detection of elevated INR by thromboelastometry and thromboelastography in warfarin treated patients and healthy controls. Thromb Res 135: 1007-1011. Link: https://goo.gl/km4b71
Nilsson CU, Strandberg K, Reinstrup P (2018) Warfarin monitoring with viscoelastic haemostatic assays, thrombin generation, coagulation factors and correlations to Owren and Quick prothrombin time. Scand J Clin Lab Invest 78: 358-364. Link: https://goo.gl/EbPmAe
Rumph B, Bollinger D, Narang N, Molinaro RJ, Levy JH, et al. (2010) In vitro comparative study of hemostatic components in warfarin-treated and fibrinogen-deficient plasma. J Cardiothorac Vasc Anesth 24: 408-412. Link: https://goo.gl/Q2NUAp
Wojcik C, Schymik ML, Cure EG (2009) Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. Int J Emerg Med 2: 217–225. Link: https://goo.gl/MCxjMv
Turecek PL, Varadi K, Gritsch H, Schwarz HP (2004) FEIBA: mode of action. Haemophilia 10: 3-9. Link: https://goo.gl/iZ7QX5
Elvstam O, Berntorp E, Schött U (2016) ROTEM monitoring of activated and non-activated prothrombin complex concentrate correction of dilutional coagulopathy. Scand J Clin Lab Invest 76: 202-207. Link: https://goo.gl/xwT2zf
Bowbrick VA, Mikhailidis DP, Stansby G (2000) The use of citrated whole blood in thromboelastography. Anesth Analg 90: 1086-1088. Link: https://goo.gl/mKUy5b
Camenzind V, Bombeli T, Seifert B, Jamnicki M, Popovic D, et al. (2000) Citrate storage affects Thrombelastograph analysis. Anesthesiology 92: 1242–1249. Link: https://goo.gl/no64mN
Sørensen B, Fenger-Eriksen C, Christiansen K, Larsen OH, Ingerslev J (2010) Evaluation of coagulation kinetics using thromboelastometry-methodologic influence of activator and test medium. Ann. Hematol 89: 1155-1161. Link: https://goo.gl/iV9A4H
Lang T, Bauters A, Braun SL, Poetzsch B, von Pape KW, et al. (2005) Multi-centre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis 16: 301-310. Link: https://goo.gl/JJ3HRP
Winstedt D, Solomon C, Hillarp A, Lundahl T, Schött U (2016) Intraoperative Hydroxyethyl Starch and its Effects on Different Fibrinogen Measurements. Clin Appl Thromb Hemost 22: 641-647. Link: https://goo.gl/8QAjE1
Buljubasic N, Akkerhuis KM, Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, et al. (2017) Fibrinogen in relation to degree and composition of coronary plaque on intravascular ultrasound in patients undergoing coronary angiography. Coron Artery Dis 28: 23-32. Link: https://goo.gl/zsQ1gQ
Spiezia L, Radu C, Marchioro P, Bertini D, Rossetto V, et al. (2008) Peculiar whole blood rotation thromboelastometry profile in 40 sideropenic anaemia patients. Thromb Haemost 100: 1106-1110. Link: https://goo.gl/eDbRbK
Cvirn G, Hoerl G, Schlagenhauf A, Tafeit E, Brodmann M, et al. (2012) Stent implantation in the superficial femoral artery: short thrombelastometry-derived coagulation times identify patients with late in-stent restenosis. Thromb Res 130: 485-490. Link: https://goo.gl/tykhjR
Gudmundsdottir BR, Francis CW, Bjornsdottir AM, Nellbring M, Onudarson PT (2012) Critical role of factors II and X during coumarin anticoagulation and their combined measurement with a new Fiix-prothrombin time. Thromb Res 130: 674-681. Link: https://goo.gl/977Mnn
Schött U (2014) Prehospital coagulation monitoring of resuscitation with point-of-care devices. Shock 41: 26-29. Link: https://goo.gl/xnBbB1
Meneghelo ZM, Barroso CM, Liporace IL, Cora AP (2015) Comparison of the international normalized ratio levels obtained by portable coagulometer and laboratory in a clinic specializing in oral anticoagulation. Int J Lab Hematol 37: 536-543. Link: https://goo.gl/C1amZx
Theusinger OM, Schröder CM, Eismon J, Emmert MY, Seifert B, et al. (2013) The influence of laboratory coagulation tests and clotting factor levels on Rotation Thromboelastometry (ROTEM(R)) during major surgery with hemorrhage. Anesth Analg 117: 314-321. Link: https://goo.gl/RvUwGi
Ågren A, Wikman AT, Holmström M, Östlund A, Edgren G (2013) Thromboelastography (TEG®) compared to conventional coagulation tests in surgical patients - a laboratory evaluation. Scand J Clin Lab Invest 73: 214-220. Link: https://goo.gl/McfWpo
Sørensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R (2011) Clinical review: Prothrombin complex concentrates--evaluation of safety and thrombogenicity. Crit Care 15: 201. Link: https://goo.gl/NChXwc
Schenk B, Würtinger P, Streif W, Sturm W, Fries D, et al. (2016) Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay. Br J Anaesth 117: 583-591. Link: https://goo.gl/MAA7Pw
Honickel M, Maron B, van Ryn J, Braunschweig T, ten Cate H, et al. (2016) Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model. Thromb Haemost 115: 271-284. Link: https://goo.gl/s9xfdJ
Peng HT, Grodecki R, Rizoli S, Shek PN (2016) A comparative study of tissue factor and kaolin on blood coagulation assays using rotational thromboelastometry and thromboelastography. Blood Coagul Fibrinolysis 27: 31-41. Link: https://goo.gl/xKuuwG
Young G, Blain R, Nakagawa P, Nugent DJ (2006) Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia 12: 598-604. Link: https://goo.gl/d2sjdN
Solbeck S, Ostrowski SR, Stensballe J, Johansson PI (2016) Thrombelastography detects dabigatran at therapeutic concentrations in vitro to the same extent as gold-standard tests. Int J Cardiol 208: 14-18. Link: https://goo.gl/XS7co6
Voils SA, Martin EJ, Mohammed BM, Bayrlee A, Brophy DF (2015) Laboratory assessment of warfarin reversal with global coagulation tests versus international normalized ratio in patients with intracranial bleeding. Blood Coagul Fibrinolysis 26: 443-447. Link: https://goo.gl/aGLFdh